Quantoom Biosciences Partners with Memorial Sloan Kettering to Advance Personalized RNA Cancer Therapies
Key Insights
Quantoom Biosciences (search) and Memorial Sloan Kettering Cancer Center have signed a non-exclusive research license and supply agreement to develop personalized cancer therapies using Quantoom's proprietary lipid nanoparticle formulation technology QCX-002 (search).
The partnership will be housed at MSK's Olayan Center for Cancer Vaccines, with plans to deploy QCX-002 (search) in at least one RNA (search)-based medicine expected to enter Phase I clinical trials.
The agreement includes options to expand the license to future developments in Quantoom's proprietary QCX library and allows MSK to evaluate other RNA (search) manufacturing technologies from Quantoom.
Quantoom Biosciences (search) has entered into a strategic partnership with Memorial Sloan Kettering Cancer Center (MSK) to advance personalized RNA (search)-based cancer therapeutics, marking a significant milestone in the application of lipid nanoparticle technology for oncology treatments.
Partnership Details and Technology Platform
The non-exclusive research license and supply agreement centers on Quantoom's proprietary lipid nanoparticle (LNP) formulation technology, Ncapsulate QCX-002 (search). Under the terms of the agreement, Quantoom will supply QCX-002 directly to MSK to enable the cancer center's research and development efforts for personalized therapeutic products targeting human cancers.
"This agreement with MSK marks a major milestone for Quantoom and validates the potential of our QCX formulation chemistries in human therapeutic applications," said José Castillo, CEO of Quantoom Biosciences (search). "It is an honor to collaborate with one of the most prestigious cancer research institutions in the world to help advance personalized RNA (search)-based medicines."
Clinical Development Timeline
The collaboration will be housed at MSK's Olayan Center for Cancer Vaccines (OCCV), which MSK describes as an "academic biohub for personalized cancer immunotherapies." As part of the initial development phase, the OCCV at MSK will target deploying QCX-002 (search) in at least one RNA (search) medicine expected to enter Phase I clinical trials.
Dr. Vinod Balachandran, Director of the OCCV at MSK, emphasized the partnership's potential impact: "We are thrilled to partner with Quantoom to advance personalized therapeutics for patients battling deadly cancers. The powerful union of cutting-edge innovation and deep expertise, such as this, is precisely what's needed to accelerate the development of breakthrough cancer medicines."
Expansion Opportunities and Future Collaboration
The agreement includes strategic provisions for future growth, with an option to expand the license to future developments in Quantoom's proprietary QCX library. Additionally, MSK will evaluate other RNA (search) manufacturing technologies developed by Quantoom, potentially paving the way for broader collaboration in the field of RNA therapeutics.
Quantoom's Comprehensive RNA Platform
Quantoom Biosciences (search) positions itself as a full-stack RNA (search) partner for mRNA (search)- and saRNA-based vaccines and therapeutics. The company's N-Force toolbox relies on three core elements: Ncode for sequence design and optimization, Ntensify for RNA production, and Ncapsulate for RNA-LNP formulation. The Ntensify solution, launched in 2023, enables fully integrated, scalable RNA production and has gained global adoption for its performance and ease-of-use.
Strategic Context in RNA Therapeutics
This partnership represents part of Quantoom's broader expansion strategy in 2025. The company has also established collaborations with TechInvention Lifecare Pvt. Ltd. for RNA (search)-based vaccine accessibility and scalability, and signed a license agreement with TriLink Biotechnologies to integrate CleanCap messenger RNA capping technology into its Ntensify platform.
The collaboration comes at a time when lipid nanoparticle innovation is increasingly linked to cancer treatment advances, with companies like NanoCell Therapeutics developing targeted LNP delivery systems for direct in-vivo generation of CAR-T cells, potentially transforming the scalability and accessibility of cellular therapies for cancer patients.